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Acromegaly is a disease mainly caused by pituitary neuroendocrine tumor (PitNET)
overproducing growth hormone. First-line medication for this condition is the use of
somatostatin analogs (SSAs), that decrease tumor mass and induce antiproliferative
effects on PitNET cells. Dopamine agonists (DAs) can also be used if SSA treatment is not
effective. This study aimed to determine differences in transcriptome signatures induced
by SSA/DA therapy in PitNET tissue. We selected tumor tissue from twelve patients with
somatotropinomas, with half of the patients receiving SSA/DA treatment before surgery
and the other half treatment naive. Transcriptome sequencing was then carried out to
identify differentially expressed genes (DEGs) and their protein–protein interactions, using
pathway analyses. We found 34 upregulated and six downregulated DEGs in patients with
SSA/DA treatment. Three tumor development promoting factors MUC16, MACC1, and
GRHL2, were significantly downregulated in therapy administered PitNET tissue; this
finding was supported by functional studies in GH3 cells. Protein–protein interactions and
pathway analyses revealed extracellular matrix involvement in the antiproliferative effects of
this type of the drug treatment, with pronounced alterations in collagen regulation. Here,
we have demonstrated that somatotropinomas can be distinguished based on their
transcriptional profiles following SSA/DA therapy, and SSA/DA treatment does indeed
cause changes in gene expression. Treatment with SSA/DA significantly downregulated
several factors involved in tumorigenesis, includingMUC16, MACC1, and GRHL2. Genes
that were upregulated, however, did not have a direct influence on antiproliferative
function in the PitNET cells. These findings suggested that SSA/DA treatment acted in
a tumor suppressive manner and furthermore, collagen related interactions and pathways
were enriched, implicating extracellular matrix involvement in this anti-tumor effect of
drug treatment.
Keywords: somatostatin/dopamine (SSA/DA) therapy, acromegaly, transcriptome, next generation sequencing
(NGS), somatotropinomaFebruary 2021 | Volume 10 | Article 5937601
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Pituitary neuroendocrine tumors (PitNETs) are benign intracranial
endocrine tumors with potentially high prevalence in the
population. Clinically significant PitNET affects approximately
0.1% of the general population, but clinically insignificant or
undiagnosed PitNET can be found in approximately 16.7% (1, 2).
Somatotropinoma, which develops from anterior pituitary
somatotroph cells, are characterized by increased synthesis and
secretion of growth hormone (GH). They constitute 10–15% of
all clinically significant somatotropinomas and usually cause
acromegaly in adults or gigantism in children with additional
comorbidities (3). Acromegaly is a rare and chronic endocrine
disorder and is characterized by abnormal growth of the
extremities, cardiovascular diseases, and metabolic disorders,
such as diabetes mellitus that is caused by increased levels of
insulin growth factor 1 (IGF-1), activated by high GH levels (4).
The goal of therapeutic strategies for this condition is to
normalize GH and IGF-1 levels, remove tumor mass and/or
stabilize tumor growth while maintaining normal pituitary
function (5). Somatotropinoma resection is recommended as the
primary therapy, but often medical treatment is chosen as the first-
line therapy to reduce tumor mass (4, 5). After PitNET resection,
often the drug treatment is then used to better control the disease
(5). Somatostatin receptors (SSTRs) are the main targets for this
therapy, and 90% of somatotropinomas express predominantly
SSTR2 and SSTR5 subtypes. If somatostatin analogs (SSAs) fail to
control IGF-1 levels, dopamine agonists (DAs) that target dopamine
receptor 2 (D2R) are used as complementary management options
(6). Although SSA and DA have demonstrated an inhibitory effect
on the secretion of both hormones and cell proliferation,
approximately one-third of acromegalic patients are resistant to
cabergoline and octreotide treatment (6).
The molecular mechanisms involved in the downstream
signaling and pharmacological resistance after SSA/DA therapy
are still poorly understood (6). Their principle inhibitory effect on
hormone secretion is mediated through the inhibition of calcium
channels and activation of potassium channels (through SSTR1,
SSTR2, SSTR5) and also by inhibition of the adenylyl cyclase-
cAMP signaling pathway (through SSTR3, SSTR4) (7, 8).
However, stimulation of other second messenger signaling
molecules, such as protein tyrosine phosphatases, plays an
important role in controlling growth caused by somatostatin/
somatostatin receptor ligands that prevent cell proliferation by
inhibition of the phosphoinositide 3-kinase (PI3K)/AKT signaling
pathway, mainly through SSTR2 or via the inhibition/activation of
MAPK signal pathways by SSTR1, SSTR2, and SSTR5 (8).
Studies have found that long-term SSA therapy is associated
with lower beta-arrestin expression levels (9, 10), by potentially
working as natural desensitization factors for the SSTR, and
expression profiles of PitNETs can change due to SSA treatment.
It has been demonstrated that several factors that act as tumor
suppressors and influence gene expression in PitNET
development, such as aryl hydrocarbon receptor-interacting
protein (AIP) and tumor suppressor gene PLAG1 like zinc
finger 1 (ZAC1), modulate the antiproliferative effects of SSA
(11–13). SSAs can induce an increase in the expression of AIPFrontiers in Oncology | www.frontiersin.org 2and ZAC1 (14, 15), suggesting that SSA treatment affects factors
related to PitNET development and clinical parameters, that
could affect not only molecular signaling but also the
transcriptional profiles of PitNET cells.
In this study, we compared differences in the total
transcriptome of PitNET patients with and without SSA/DA
treatment before surgery. Our objective was to determine
whether the transcriptome signature could distinguish those
acromegaly patients that had been on therapy with those that
had not, and also to identify candidate genes whose expression is
affected by SSA/DA treatment.MATERIALS AND METHODS
Sample and Data Collection
All somatotropinoma tissue samples were obtained from patients
who underwent planned resections at Pauls Stradins Clinical
University Hospital, Latvia. All patients were recruited from the
Genome Database of the Latvian population (LGDB), a
government-funded national biobank (16), and all biobank
activities and research in this article comply with the
Declaration of Helsinki. Broad informed consent for LGDB and
project-specific consent for research involving the pituitary tumors
were obtained from all patients. Both the biobank and PitNET
research was approved by the Central Medical Ethics Committee
of Latvia (protocol No. 22.03.07/A7 and 01.29.1/28, respectively).
Sample collection and the research process both complied to the
Declaration of Helsinki. After resection, PitNET tissue samples
were stored in RNAlater® Solution (Thermo Fisher Scientific,
USA) and stored for up to 24 h at +4°C and then at −20°C for up
to 2 months, until DNA/RNA extraction.
Total RNA Extraction From Pituitary
Neuroendocrine Tumor Tissue
Twenty to 30 mg of PitNET tissues was homogenized using a
FastPrep-24™ homogenizer in RLT Plus buffer in Lysing Matrix
D 1.5 ml tubes (MP Biomedicals, USA), and total RNA was
extracted with AllPrep DNA/RNA Mini Kit (Qiagen, Germany)
and stored at −80°C. Total RNA quality control was carried out
using Agilent 2100 bioanalyzer and an Agilent RNA 6000 Pico
Kit (Agilent Technologies, USA), and concentration was
measured using Qubit 2.0 fluorometer and Qubit™ RNA HS
Assay Kit (Thermo Scientific, USA).
Transcriptome Library Preparation
and Sequencing
Transcriptome libraries were prepared with the Low Input
RiboMinus™ Eukaryote System v2 and Ion Total RNA-Seq Kit
v2 (Thermo Fisher Scientific, USA) following the manufacturer’s
instructions. The average concentration of total RNA was 88.15
ng/µl (range: 35.2–138 ng/µl). Input amount for the transcriptome
library preparation was 500, ng and the average library
concentration was 23.55 ng/µl (8.91–31.8 ng/µl) with an average
fragment length of 214 bp (189–236 bp). The preparation of
transcriptome libraries was carried out in relation to 1:1 based on
patient samples who had or had no medical therapy beforeFebruary 2021 | Volume 10 | Article 593760
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sequenced at the Latvian Biomedical Research and Study centre,
Genome Centre Core facility using the Ion Proton™ System for
Next-Generation Sequencing (Ion OneTouch and Ion PI™ Hi-
Q™ OT2 Reagents 200 Kit for emulsion PCR and Ion PI™ Hi-
Q™ Sequencing 200 Solutions kit and Ion PI™ Chip V3 chips for
sequencing, all from Thermo Fisher Scientific, USA). Libraries
were sequenced three to four times to acquire at least 20 M reads
per sample, and at least 10 M would represent uniquely mapped
reads, so that the rRNA content would not reach 50% of the
sample. For sample PA05, 20 M of total reads was not achieved,
and uniquely mapped reads were close to 7 M. Nevertheless, the
relevant sample was included in the data analysis based on a 2014
study by Liu et al., analyzing the effects of read number and
biological repetitions on differentially expressed genes (DEGs).
They concluded that by increasing the amount of biological
repetitions independent of the number of reads from the sample
library, they were able to increase the number of DEGs and logFC
resulting in increased accuracy of expression levels and greater
efficiency in the resulting analysis (17).
Data Analysis
Transcriptome data has been deposited in an online repository
(GEO Submission GSE160195). Differentially expressed genes
were obtained using the DESeq2 (v1.26.0) package (18) from the
Bioconductor (v3.10) project (19) and R (v3.6.1) software (www.r-
project.org). Read counts were first filtered based on read count
frequency in all samples. Genes with at least ten reads in at least
three samples were included in the analysis. To detect sample
outliers, read count data were transformed with variant stabilizing
transformations (VSTs), considering the design of the experiment
and visualized with sample distance heat mapping, PCA and MDS
methods. Read count density visualization was used to check for
problematic samples. Counts were replaced with trimmed mean
values for genes which were marked as outliers based on their
dispersion Cook’s distance values, which were calculated as the.99
percentile of the F (p, m − p) distribution for each gene. To
account for batch effects, surrogate variables (SVAs) were
calculated using the sva (v3.34.0) package (Bioconductor project)
and added to the design matrix. DESeq function call was then used
on raw data but filtered by read count frequency counts to detect
DEGs. “Independent Hypothesis Weighing” (IHW) was specified
as the independent filtering method, which is not the default in
DESeq2, to gain statistical power for testing, using the IHW
(v1.14.0) package (20), which uses the base mean value of
counts for each gene, in this case, as a weight for the adjusted p-
value calculation. Next, we performed log fold shrinkage with the
apeglm (v1.8.0) package (21), which uses the heavy tailed Cauchy
prior distribution, to account for extra variability that comes from
genes with low counts and high dispersion values. All parameters
were left at their default values, except for “coef” which lets us
denote which design coefficient we want to perform shrinkage on.
Genes with FDR <0.05 and transformed absolute logFC value >1.5
were deemed as significant and selected. To visualize differential
expression results, a heatmap was constructed with the pheatmap
(v1.0.12) package using the differences from means across all
samples of the VST normalized counts for each gene. HeatmapFrontiers in Oncology | www.frontiersin.org 3data was clustered both by genes and samples using the kmeans
algorithm. A volcano plot was also plotted with the Enhanced
Volcano (v1.4.0) package using the same log fold shrinkage values
obtained from apeglm. Kendall’s Tau correlation analysis between
read count matrix and Knosp classification index and between
read count matrix and Ki-67 proliferation index was performed to
test whether these factors affect the expression levels of detected
DEG’s and whether they should be included in the model (22). To
further assess potential relationships between the significant
differentially expressed genes and their link to a common
signaling pathway or functional protein–protein interaction,
enrichment analysis was carried out between statistically
significant DEGs, using the STRING (v11.0) database (23), with
the significance threshold set at 0.4. Experiments, databases, co-
expression, neighborhood, gene fusion and co-occurrences were
all set as sources for active interactions. The enrichment was
performed by calculating the probabilities for each of the selected
evidence sources, a prior was set to account for random
interactions between two proteins and then the probabilities are
added. A homology correction was added to the co-occurrence
score. Finally, we annotated the DEGs using the Gene Ontology
(GO) (release: 2020-01-01) (24) and GO enrichment analysis tools
(25) and functional annotation tool from the DAVID
Bioinformatics Resources 6.8 database (26), as well as gene set
enrichment analysis (GSEA) with fgsea (v1.14.0) (minGSsize = 10,
maxGSsize = 1,000) and clusterProfiler (v3.16.1) packages, from
the Bioconductor project. All scripts used in the study are in
Supplementary Material 1 and deposited in GitHub portal
(https://github.com/rsak-384/PitNET-after-therapy).
Selection of the Validation Cohort
We searched online data repositories and the literature for PitNET
transcriptome data, with SSA and/or SSA/DA treatment status
before surgery. From the studies closely matching our own, we
found transcriptomes of ten somatotropinomas with and without
SSA/DA therapy, from the “Pangenomic Classification of Pituitary
Neuroendocrine Tumors” study (27) which were carefully chosen
using the “ArrayExpress” archive of functional genomics data.
Both therapy and nontherapy group samples were screened using
the mentioned metadata, to ensure that the samples were as
similar as possible between both groups, in terms of clinical
data, in order to maximize the likelihood of detecting a true signal.
Cell Line Culture and Stimulation
The rat pituitary GH3 cell line was obtained from ATTC. GH3
cells were maintained in F-12Kmedium supplemented with 2.5%
fetal bovine serum, 15% horse serum, penicillin (100 U/ml) and
streptomycin (100 µg/ml).Cells were cultured at 37°C in a
humidified incubator containing 5% CO2. For the gene and
protein expression experiments, cells were grown on a 6-well
plate at a density of 1.5 × 106 cells/well and treated with 0.1 µM
and 1 µM octreotide for 4, 8, and 24 h.
RNA Extraction and Quantitative
Real-Time Polymerase Chain Reaction
Total RNA was isolated from GH3 cells usingTRIzol reagent,
according to the manufacturer’s protocol. First-strand cDNAFebruary 2021 | Volume 10 | Article 593760
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kit (ThermoFisherScientific). qRT-PCR was performed
using Absolute Blue SYBR green MasterMix reagent (Thermo
FisherScientific) with a ViiA7 real-time PCR detection system
(AppliedBiosystems). The primer pairs that were employed for
MUC16 were forward 5′-GCCTAGGAAGAACCAAAACTCA-
3′ and reverse 5′-TCCAATGTGTAGTTCCCCAGT-3′; for
GRHL2 were forward 5′-CCTCTGCCTGAGTCAAGACC-3′
and reverse 5′-TAGGAGCTGTGGCTGGCTAT-3′ ; for
MACC1 were forward 5′- CCTGGATGCCTTAGGTGGTA-3′
and reverse 5′-CCCACCCAGGACTCTGATTA-3′; for GUSB
were forward 5′-GACTGATCCTTCCATGTATCCCA-3′ and
reverse 5′-CCCGCATAGTTGAAGAAGTCG-3′. mRNA levels
were quantified and normalized to levels of reference gene GUSB
using the 2−DDCt method and presented as relative expression
compared with values of untreated cells.Western Blot
Total protein samples from control and octreotide treated GH3
cells were extracted by RIPA buffer (50 mM Tris-HCl; pH 8.0, 150
mM NaCl, 5 mM EDTA, 1% Igepal CA-630, 0.5% sodium
deoxycholate, 0.1% SDS, and supplemented with Halt™
protease inhibitor cocktail; Thermo Fisher Scientific). Protein
concentration was quantified with BCA Protein Assay reagent
(Thermo Fisher Scientific), according to the manufacturer’s
instructions. Lysates (45 µg) were electrophoresed through a
10% SDS-PAGE gel and transferred to Hybond-C-extra
nitrocellulose membranes (Amersham Biosciences) for 45 min
in a semi-dry transfer system. Membranes were blocked with 5%
non-fat milk in TBS-T buffer (20 mM Tris, pH 7.6, 137 mMNaCl,
and 0.05% Tween 20) for 1 h at room temperature. Membranes
were incubated with 1 µg/ml MACC1(PA5-20758, Thermo Fisher
Scientific) and 1 µg/ml b-actin (ab8224, Abcam) primary
antibodies for 1 h at room temperature and incubated with
horseradish peroxidase-conjugated anti-mouse IgG (sc-2005,
Santa Cruz Biotechnology) and anti-rabbit (sc-2004, Santa Cruz
Biotechnology) secondary antibodies for 1 h at room temperature.
Membranes were then washed in TBS-T buffer three times and
developed with Pierce ECL western blotting substrate (ThermoFrontiers in Oncology | www.frontiersin.org 4Fisher Scientific). UVP software VisionWorks LS (Thermo Fisher
Scientific) was used to capture signals.RESULTS
Characterization of the Study Group
For all the patients within this study (Table 1), it was their first
time diagnosis of somatotropinoma, displaying clinical
symptoms of acromegaly (ICD-10, E22.0). One patient (PA11)
had tumor with complementary prolactin expression
(Supplementary Material Figure 1). All patients had primary
PitNET having a tumor over 10 mm, at least in one dimension.
Patient’s mean age at the time of diagnosis of PitNET was 43
years (age distribution varied from 22 to 65 years). Ten were
females, and two were males. Three patients had SSA/DA
therapy and three SSA treatment before PitNET resection, and
six patients did not have SSA/DA treatment. We are fully aware
that the use of DAs in our study group was more frequent than
usual. This could be explained by the fact that not all patients
agreed to surgical therapy immediately, and therefore, the
preoperative treatment period in most cases in our cohort was
longer than 3–6 months. In turn, if IGF-1 remains modestly
elevated during SSA administration, the proposed algorithm
recommends adding cabergoline to the treatment plan.
Differentially Expressed Genes
A total of 18,266 genes remained after sequencing read count
filtering, based on the presence of gene expression in at least
three samples. Raw counts were replaced for 691 genes as they
were flagged as outliers. Three statistically significant surrogate
variables were detected with the SVA package and were included
in the analysis model. Differential expression analysis between
the non-therapy group and the therapy group with DESeq2 and
log fold shrinkage with the apeglm algorithm detected 40 DEGs
after applying thresholds of logFC >1.5 and P-adj <0.05. In total
34 (85%) DEGs were upregulated with a median logFC of 3.02
(IQR = 1.73), and six (15%) genes were downregulated with a
median logFC of −2 (IQR = 0.64). Even though two distinct













PA01 41 F Somatotropinoma Macro/2 <1%/no data SSA, DA/2 years
PA02 25 F Somatotropinoma Macro/1 <1%/sparsely SSA/1 year
PA03 31 M Somatotropinoma Macro/4 5%/no data SSA/3 month
PA04 31 F Somatotropinoma Macro/1 5%/sparsely SSA, DA/2 years
PA05 40 M Somatotropinoma Macro/0 <1%/no data SSA, DA/2 years
PA06 22 F Somatotropinoma Macro/4 1%/densely SSA/3 month
PA07 60 F Somatotropinoma Macro/1 3–4%/sparsely No
PA08 53 F Somatotropinoma Macro/1 <1%/no data No
PA09 65 F Somatotropinoma Macro/4 12%/densely No
PA10 53 F Somatotropinoma Macro/2 1–2%/no data No
PA11 31 F Somatotropinoma co-secreting
prolactin
Macro/3 9%/densely No
PA12 62 F Somatotropinoma Macro/1 3%/no data NoFebruary 2021 | Volume 10 | Article 593760
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they were not removed because both samples passed sample
quality evaluation using FastQC. Two distinct sample groups
were observed in the heatmap (Figure 1A) that were derived
from clustering. These visual results are concordant with the two
patient groups, with and without therapy, that were used in the
study design.
Volcano plot using apeglm transformed log-fold change
values presents the distribution of differentially expressed genes
based on their log fold changes while being controlled for genes
with low counts or abnormally high dispersion values. These
manipulations confirmed that most of the DEGs had increased
expression when comparing samples receiving therapy to those
with no therapy (Figure 1B).
The three most upregulated genes in the treated group were
metallophosphoesterase domain containing 1 (MPPED1),
transmembrane protein 132C (TMEM132C), and septin 14
(SEPTIN14); in contrast, the three most downregulated genes
in the SSA/DA and SSA therapy groups were grainyhead like
transcription factor 2 (GRHL2), mucin 16 (MUC16), and MET
transcriptional regulator (MACC1—Metastasis-Associated in
Colon Cancer) (Table 2, Figure 2). Furthermore, OLFM2
displayed the most consistent statistically significant differential
upregulation in all the SSA/DA and SSA therapy group samples
as indicated by low variance, high logFC difference, and P-value.
logFC, P values, and box plots for all the significant DEGs are
presented in Supplementary Material Tables 1 and 2.Frontiers in Oncology | www.frontiersin.org 5By performing Kendall’s Tau correlation analysis between the
read count matrix and Knosp classification index and Ki-67
proliferation index, no coherent correlation trend could be
observed across all DEG’s for either of the potential factors;
therefore there is no reason for their inclusion in the differential
expression model Supplementary Material Table 3).
Protein–Protein Interactions and Pathway
Analysis
By visualizing protein–protein interactions between all of the
significant DEGs using STRING database, we were able to
identify five potential interactions between the proteins of the
following genes: COL8A2, COL16A1, SLC8A2, COL6A1,
SLC6A1, ADAMTSL2, and ADAMTS10. According to the
database protein interaction analysis results, the number of
expected interactions (edges) in the network was one, but the
achieved number was five, with a PPI enrichment p-value of
0.00022, meaning that our network holds more reciprocal
interactions than would be expected if the same amount of
random proteins where to be drawn from the genome (Figure 3).
The protein for the gene LINC01529 could not be identified for
Homo Sapiens; therefore, it was not included in the resulting
network hence the final network consisted of protein interactions
for 39 DEGs. Specific sources and their contribution for each pair
of interactions are presented in Supplementary Material Table 4.
To determine which molecular mechanisms could be affected
by the DEGs, GO enrichment analysis was performed along withA B
FIGURE 1 | Heatmap (A) of the statistically significant differentially expressed genes. Heatmap intensities were obtained by filtering apeglm transformed log fold change
values with the following thresholds: abs. lfc >1.5 and padj <0.05. The color scale represents the approximate difference in each individual sample from the average, vst
normalized read counts for that gene. Data is clustered both by genes and samples using the kmeans algorithm included in the pheatmap package. Volcano plot (B) of
differential expression results with apeglm transformed log fold change values. Dashed vertical lines represent absolute log fold change threshold of 1.5 and horizontal
dashed line represents p values threshold of 1.31e-4 or FDR ~0.05. Red dots represent significantly DEGs (FDR < 0.05 and absolute L2FC > 1.5).February 2021 | Volume 10 | Article 593760
Saksis et al. Pituitary Tumor Transcriptome After TherapyFIGURE 2 | Box plot diagrams displaying raw read count distribution at the log10 scale for both the SSA/DA treated and untreated groups for the seven DEGs
(OLFM2, MACC1, GRHL2, MUC16, TMEM132C, SEPTIN14, MPPED1), with the top L2FC positive and negative changes and for DEGs with the lowest FDR
value (OLFM2).TABLE 2 | Top three differentially expressed genes based on their logFC values.
Gene symbol Gene name logFC lfcSE P-adjusted Expression
MPPED1 Metallophosphoesterase Domain Containing 1 6.236 1.898 0.0058 Upregulated
TMEM132C Transmembrane Protein 132C 6.109 1.325 0.0003 Upregulated
SEPTIN14 Septin 14 5.134 1.242 0.0007 Upregulated
MACC1 MET Transcriptional Regulator MACC1 −2.181 0.512 0.0001 Downregulated
MUC16 Mucin 16, Cell Surface Associated −2.485 0.839 0.0339 Downregulated
GRHL2 Grainyhead Like Transcription Factor 2 −4.017 1.126 0.0077 DownregulatedFrontiers in Oncology | www.frontiersin.org 6 February 2021 | Volume 10 | Article 593760
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submitted list of DEGs (FDR < 0.05) were found to be
significantly enriched in multiple pathways categorized as a
part of the “Cellular component” annotation data set. The
majority of these results are associated with either the plasma
membrane, extracellular matrix (ECM), or synapses (Table 3).
By performing KEGG pathway analysis as a part of DAVID,
we obtained one significantly (FDR < 0.05) enriched pathway for
protein digestion and absorption. However, by performing
Reactome pathway analysis in the same run, we obtained
multiple significant hits, which were associated with collagen
processes, glycosylation, and cell surface interactions (Table 4).
When applying GSEA analysis six signaling pathways were
detected as significantly enriched (P-adjusted < 0.05) in the
discovery cohort with the Molecular Signature Database (v7.2)
(MSigDB) hallmark gene sets, and one signaling pathway was
detected when using the KEGG gene set from the cluster Profiler
package. Protein digestion and absorption were the only signaling
pathway to overlap when using results from DAVID and those of
GSEA. We also assessed the involvement in signaling pathways
related to cell proliferation, growth, and apoptosis of individual
DEGs identified in our study (full pathway list in Supplementary
Material Table 5) and identified that QPRT, SEPTIN14, CLU,
PTGS2 are involved in following pathways ALCALA_
APOPTOSIS, GO_CELL_CYCLE, HALLMARK_APOPTOSIS,
G O _ C E L L _ C Y C L E a n d GO _ R E S P ON S E _ T O _Frontiers in Oncology | www.frontiersin.org 7TUMOR_NECROSIS_FACTOR (Supplementary Material
Table 5).Validation by Independent Data Set
To test for biological reproducibility of the experiment, the
aforementioned 10 samples were run through the exact same
workflow to determine differential gene expression detection as
before, resulting in 88 significant DEGs (FDR < 0.05 and logFC> ±
1.5), 70 (79.55%) of which were upregulated, with a median logFC
of 2.71 (IQR = 1.67) and 18 (20.45%) downregulated, with a
median logFC of −2.1 (IQR = 0.59). From these 85 DEGs, amyloid
beta precursor protein binding Family A member 2 (APBA2) was
the only one differentially expressed in both discovery and
validation cohorts, with logFC of 2.83 in the discovery cohort
and 3.31 in the validation cohort.
Gene set enrichment analysis was performed on the
validation cohort to test whether there may be any overlapping
signaling pathways between both sets of samples. No overlapping
signaling pathways, however, were detected although 478
signaling pathways were found in the publication repository
data when using the MSigDB hallmark set and five when using
the KEGG pathways analysis (27).
Discovery set DEGs were also cross validated with leading
edge genes from the significant validation cohort pathways. Three
genes were confirmed to be involved in multiple pathways,FIGURE 3 | Visual representation of protein–protein interaction enrichment analysis between the statistically significant 39 out of 40 DEGs using STRING (v11.0)
database. The line thickness between the connected nodes indicates the strength of the supporting data. Experiments, databases, co-expression, neighborhood,
gene fusion, and co-occurrence.February 2021 | Volume 10 | Article 593760
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Material Table 6).
Functional Characterization in GH3 Cells
To functionally characterize potential effects of SSA on MUC16,
GRHL2, and MACC1, we treated GH3 cells with octreotide and
observed changes in expression by real-time PCR for all three
candidates and Western blot for MACC1. The results
demonstrate that octreotide inhibits RNA expression of all
three factors with most inhibition after 4 h of treatment. The
MACC1 protein expression was also inhibited after octreotide
stimulation and the most decrease inMACC1 level was observed
after 24 h (Figure 4).DISCUSSION
The first-line medical management of somatotropinomas is the
use of SSAs, causing reduced tumor cell proliferation and
hormone secretion. If the control of IGF-1 is not achieved,Frontiers in Oncology | www.frontiersin.org 8DAs are added to the treatment regimen. The targets of this
therapy are SSTRs and D2Rs that alter intracellular signaling to
promote an antiproliferative effect, and there is indirect evidence
that this may lead to altered gene transcription. However, the
effects of SSA/DA medication on the overall cellular
transcriptional profile and consequent functional changes have
not been elucidated. This is one of the first reports that have
evaluated transcriptome profiles from PitNET tumor tissue in
two groups of patients with and without medical therapy, which
was applied before tumor resection. As a result, we were able to
distinguish tumor preoperative treatment status based on
transcriptome profiles. We found 40 DEGs potentially affected
by SSA/DA treatment, with significant downregulation seen in
several tumorigenesis promoting factors. We extended these
findings by applying pathway analysis, which revealed an
alteration in the expression of collagen related genes.
Many studies have analyzed the influence of SSA on cell
signaling components, and these involve major effects on SSTR1,
SSTR2, and SSTR5 binding and alteration of the PI3K/AKT and
















8/424 10.1 CILP, CLU, COL16A1, ADAMTS10, BCAM, COL8A2, COL6A1, SSC5D 1.10−6 0.001
GO:0031012 Extracellular
matrix
9/566 8.5 ADAMTSL2, CILP, CLU, COL16A1, ADAMTS10, BCAM, COL8A2, COL6A1, SSC5D 8.64−7 0.002











11/1228 4.8 ARC, PDE4A, PTGS2, SLC6A1, ATP1B2, SLC8A2, THBD, GRIK3, PDE6A, OLFM2, CALB2 1.10−5 0.004
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GO:0030054 Cell junction 13/2073 3.4 ARC, SV2B, NPTX1, SLC6A1, DTNA, ATP1B2, CLU, SLC8A2, GRHL2, GRIK3, APBA2,
OLFM2, CALB2
6.34−5 0.014
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GRIK3, AHNAK2, COL6A1, DIRAS2, STUM, SSC5D, APBA2, PDE6A, OLFM2,
ST6GALNAC5, CALB2
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acromegaly patients (28), but the underlying causes were not
clear. The only study to date that has assessed the impact of SSA
as a pre-operative treatment on transcriptome profiles from
PitNETs has been carried out on three somatotropinomas and
was compared to untreated PitNETs (29). The authors detected
decreased Ki-67 expression in the pre-treated group and
increased MUC1 and CD40 expression (29). In our data, we
did not observe a significant correlation of Ki-67 with treatment
status; however, we observed that overall read counts in PitNET
patients without treatment were higher (Supplementary
Material Table 7); to identify more pronounced association
the larger sample group would be required but the tendency
could be observed.
Our data indicated that three genes having pronounced effects
on tumorigenesis were strongly downregulated by SSA/DA in
somatotropinoma tissues (MUC16, MACC1, and GRHL2) and
confirmed these findings in functional GH3 cell experiments.
MUC16 is a high molecular weight O-glycosylated protein.
Elevated levels of MUC16 in the blood serves as a prognostic
biomarker for ovarian cancer (30). MUC16 has also been
implicated in the development of other neoplasms and as a
potential marker in pancreatic, breast and lung cancers (31–33).Frontiers in Oncology | www.frontiersin.org 9The second candidate, MACC1 was involved in epithelial–
mesenchymal transition and was potent regulator of cancer
metastasis and cell invasion. Increased expression of MACC1
leads to greater proliferation, induction of angiogenesis, and is
antiapoptotic in various cancers (34, 35). Therefore, over the
twofold decrease of MACC1expression observed in our data due
to SSA/DA treatment is in line with previous results in
the literature.
The third factor identified in this study GRHL2 was DNA-
binding nuclear protein, containing a highly conserved DNA-
binding domain (36). It was involved in the regulation of various
developmental processes such as closure of the neural tube and
the regulation of progenitor cell functions during the
development of the pituitary gland. GRHL2 is expressed in
pituitary progenitor cells and in mice with decreased pituitary
progenitor cell numbers (37). GRHL2 has been implicated in
many cancers such as breast, lung, colorectal, gastric, ovarian,
and prostate. However, its role as tumor promoter or as an anti-
tumor factor appears to be tissue dependent (36).
The three genes that were most strongly upregulated by SSA/
DA treatment in somatotropinoma tissues were MPPED1,
TMEM132C, and SEPTIN14, potentially having more indirect
evidence for their involvement in anti-tumor effect.TABLE 4 | Pathway enrichment analysis results (FDR < 0.05).
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it is involved in the development of the central nervous system
(38). No other functional studies have been performed on this
candidate. However, as a member of metallophosphoesterase
proteins, the related MPPED2 has been shown to have
pronounced tumor suppressor activities. Downregulation of
MPPED2 has been demonstrated in neuroblastoma and breast
cancer (39, 40).MPPED1 andMPPED2 show over 71% similarity
based on Ensembl.org data, but to determine whether they have
related functions needs further investigation.
Information concerning a potential function for the second
upregulated candidate, TMEM132C, is modest. TMEM132 family
proteins are thought to be involved in cell adhesion (41), while
other members of this protein family have been associated with
insomnia, hearing loss, panic disorder, and anxiety behavior (41).
Somatic variants in the related factor TMEM132D have beenFrontiers in Oncology | www.frontiersin.org 10found in small-cell lung and pancreatic cancer (42, 43). One
report has implicated the cg04475027 methylation site on
TMEM132C, as a marker for breast cancer (44).
The third factor, SEPTIN14 belongs to the septin protein family
of GTP-binding membrane-interacting proteins and has a
function in cytoskeleton organization, cytokinesis, apoptosis, cell
polarity, and cell cycle regulation (45). Studies have found that
aberrant expression of septin, may induce antiproliferative and
tumor suppressive effects (46, 47), and somatic variants of
SEPTIN14 have been demonstrated in skin and gastrointestinal
cancers (48).
As SSA treatment effect induces shrinkage of the tumor, it
would be expected that SSA leads to alterations in cell
proliferation, growth, apoptosis, and related pathways. Indeed,
four of the individual DEGs (QPRT, SEPTIN14, CLU, PTGS2) in
our study are involved in these pathways (SupplementaryA
B
FIGURE 4 | Effect of octreotide on MUC16, GRHL2, and MACC1 gene expression in GH3 cells. (A) Cells were treated with 0.1 µM and 1 µM octreotide for 4, 8, and
24 h. Gene expression was analyzed by real-time PCR and expressed relative to value from untreated control cells, which was defined as 1. Data were normalized to
GUSB and values were calculated using a comparative (2-DCt) method. Results are mean ± SD from two independent experiments. (B) Western blot analysis of MACC1
protein expression in octreotide treated GH3 cells. b-actin was used as a loading control. The experiments were performed twice with similar results.February 2021 | Volume 10 | Article 593760
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relevant cell proliferation pathways, but what effect these DEGs
constitute on whole pathway in the cells of PitNETs remains to
be discovered.
The altered expression of CLU gene that encodes for custerin
involved in apoptosis and clearance of cell debris has been also
identified related to invasiveness traits in two PitNET studies (49,
50). We, however, did not observe this on the pathway level in
the results of enrichment analysis and protein–protein
interactions, but our data supported ECM related pathways
(Table 4). Further investigation is needed to elucidate whether
the period of SSA/DA treatment could influence the intrinsic
transcriptomic regulation of PitNETs over the course of the
therapy. As at the very start of the therapy, the signaling
pathways could be active that slow the tumor growth, but
afterwards, other pathways involved in the reduction of tumor
mass that could involve the ECM reorganization could be more
pronounced. It has been shown that the most reduction of tumor
mass occurred during the first year of SSA treatment (5). These
assumptions should be further studied as there is only one study
to date considering the impact of SSA preoperative treatment of
PitNET transcriptome (29). This study has also found altered
expression of one of the mucin family factorsMUC1, while in our
study we found MUC16 as one of the most significant DEGs.
Other transcriptomic studies that could be compared to our
results are reports that have assessed the invasiveness of the
PitNETs. The invasiveness could also be related to increased cell
growth, and in PitNETs, it has been demonstrated that resistance
to SSA is accompanied with reduced tumor shrinkage (51). In the
transcriptome studies comparing invasive and non-invasive
PitNETs, there are various candidates identified that are
related to cell proliferation, growth, apoptosis pathways, but
still rarely these candidates overlap between the studies (49, 50,
52–58) (Supplementary Material Table 5). These numerous
studies demonstrate various intrinsic mechanisms that in large
scale studies lead to heterogeneity in the observed DEGs. Mostly
this difference arises from variation in design and diagnoses, but
also notable is the usage of small groups to obtain conclusions.
Small group comparison (which is one of the weaknesses of this
study) is more likely to lead to spurious findings, although it’s
clear that obtaining large homogeneous groups of the rare
heterogeneous condition is a challenging task in itself. The lack
of reproducibility in these literature data could also be attributed
to sample size variation and use of the different methodologies.
Although the majority of DEGs detected here were
upregulated (34 DEGs) after treatment, three of six genes that
were downregulated appear to have functions more related to
tumor pathogenesis, according to current literature. Thus, we
propose that the influence of SSA/DA treatment at the
transcriptome level was directed toward suppression of tumor
promoting genes (GRHL2, MUC16, MACC1), and the protective
effects of the upregulated DEGs were small or indirect (MPPED1,
TMEM132C, SEPTIN14); however, further studies are needed to
confirm this hypothesis.
Interestingly, olfactomedin 2 (OLFM2) was found to be
significantly upregulated in all tumor tissues from the SSA/DAFrontiers in Oncology | www.frontiersin.org 11treated group (Figure 1B). OLFM2 is involved in vascular
remodeling, scar tissue formation in blood vessels, and smooth
muscle differentiation. Elevated levels of OLFM2 can be found in
blood plasma interventional therapy with postoperative
restenosis (59–61). Vascular plasticity is an important hallmark
of malignant tumors (62), but whether SSA administration can
lead to blood vessel remodeling events in PitNET tissue,
promoting protective anti-tumoral effects needs to be
functionally assessed. Furthermore, OLFM2 is involved in
interactions with the transcription factor Runx2 (59), which
has been reported to be involved in the regulation of pituitary
tumor growth (63, 64).
Protein–protein interactions and pathway analysis revealed
potential interactions between COL8A2, COL16A1, SLC8A2,
COL6A1, SLC6A1, ADAMTSL2, ADAMTS10 (Figure 3) and
several significantly enriched pathways belonging to the
“Cellular component” category (Table 3), which again
demonstrated the lowest FDR scores for pathways including
COL16A1, COL6A1, and COL8A2 suggesting collagen related
effects upon SSA/DA treatment (Table 4).
Collagens are key components of the ECM and can affect the
behavior of tumor cells, for example proliferation, differentiation,
motility, and metastasis. Tumor mass usually consists of tumor
cells and stroma, which is composed of the ECM. Tumor cells
and stroma interact with each other and affect tumorigenesis and
cellular characteristics. It has been reported that PitNETs can
have elevated fibrotic scar tissue primarily composed of stromal
collagens (65–67). Furthermore, research on collagen-producing
cells in PitNETs and normal pituitary suggests that properties of
collagen production during tumorigenesis can change, leading to
the formation of fibrosis in PitNETs (68). Interestingly, collagen
type VI alpha 6 (COL6A6) is downregulated in PitNETs, and
overexpression of this collagen caused anti-tumoral effects and
decreased metastatic capacity (69).
Some studies investigating preoperative SSA administration
have demonstrated that this treatment helps to reduce tumor
mass and soften the tumor tissue, facilitating tumor resection
(70, 71). However, other reports have not observed this (72), or
whether the tissue softening could be related to ECM alterations.
Overall, our data suggested that ECM remodelling, in particular
collagen regulation, might be involved in SSA/DA treatment, but
further investigations are still required to determine the
underlying interactions.
The ECM is an essential part of the tumor microenvironment,
that along with other participating factors, may affect cell
signaling, molecular transport, metabolic pathways, and
immune resistance mechanisms largely contributing to tumor
growth and invasiveness (73). Some tumors are composed of
even up to 60% of ECM that is due to fibroblast infiltration that
produces excessive amounts of ECM and is associated with
worth prognostics (74, 75). Various collagen dysregulation has
been linked with tumor properties of many malignant cancers
(76, 77). In our study the SSA/DA treatment could impact the
expression of these proteins due to remodeling and
restructuration of the ECM; both ADAMTS proteins and
collagens could be responding to treatment induced reductionFebruary 2021 | Volume 10 | Article 593760
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this hypothesis.
We also discovered “protein digestion and absorption” with
both pathway enrichment methods that might imply molecular
mechanisms’ underlying effects of SSA/DA treatment. Besides
tumor microenvironment, also metabolic reprogramming could
affect properties of tumor cells. It has been recognized that
alterations in metabolic regulation of tumor cells occur that
drives accelerated proliferation, growth, and survival via an
increase in glycolysis, amino acid, and lipid metabolism, and
mitochondrial biogenesis (78, 79). There are many studies
considering the role of conventionally administered
medications (metformin, sulfasalazine, proton pump inhibitors
and other) for non-malignant disorders that target metabolic
reprogramming of tumors and have beneficial effects on cancer
treatments (78, 79); whether SSA could have a similar effect is an
interesting topic for investigation. It is known that SSA has
effects on PI3K/Akt signaling pathway (8) that is one of the
important factors inducing cancer metabolic reprogramming
(78). Therefore, the SSA could exert its activity on beneficial
anti-tumoral effects via shifts in tumor cell metabolism, but this
needs to be investigated further.
From our computational validation of the data from online
available data sets of PitNET tissue transcriptomes, from patients
with and without therapy (27), we discovered one candidate
factor and (APBA2) several potentially involved pathways
(related to THBD, BCAM and APBA2). THBD is expressed on
endothelial cells that were found to be involved in blood
coagulation (80). Further investigations are still needed,
however, in order to determine the role of these factors during
SSA/DA treatment. BCAM is a plasma membrane glycoprotein
that can bind ECM proteins and has been reported to be
expressed in both fetal and adult rat pituitary (81), however,
the precise role of this protein in the pathogenesis and therapy of
PitNET needs further study. The only candidate that was found
to be differentially expressed in our results and in validation data
is APBA2; this protein interacts with amyloid precursor proteins
which are involved in the development of Alzheimer’s disease. It
has been reported that APBA2 is involved in gonadotropin-
releasing hormone-1 neuronal migration to the pituitary and
neurogenesis (82). The decreased expression of APBA2 has been
identified in superior temporal gyrus in schizophrenia patients
(83) and gender-specific alterations in the expression of APBA2
have been found in dopamine neurons (84). According to
Protein Atlas information, this protein is involved in signal
transduction and vesicular trafficking in the central nervous
system, and these actions could be related to different levels of
PitNET functioning, development, or progression as well as
response to SSA/DA treatment. But the precise functionality of
APBA2 within the nervous system signaling or trafficking as well
as the pathogenesis of PitNETs is not clear and needs to be
further studied.
The potential candidates involved in SSA/DA effects in our
data are not directly linked to previous reports relating to
resistance mechanisms of SSA. We did not find any significant
profile changes in SSTR, beta-arrestin, or cytoskeleton proteinFrontiers in Oncology | www.frontiersin.org 12filamin A that was associated with drug resistance mechanisms
(85). It has also been reported that SSTR2 and D2DR agonists can
reduce migration and invasiveness of PitNET cells that are
mediated via cofilin and filamin A mechanisms (86–88). We did
not observe a significant alteration in expression of these factors,
however, in our transcriptome data. Nevertheless, our results
indicated novel factors targeted by SSA/DA (GRHL2, MUC16,
MACC1) that merit further exploration, so as to characterize their
role in SSA responder and non-responder groups that could give
more insight into the relation of these factors to drug resistance.
The limitation of this study was the small number of samples
used; however, our main goal was to demonstrate that SSA/DA
could cause distinct alterations in transcriptome profiles from
PitNET tumors, and this has been convincingly demonstrated.
Although the results indicate proof of principle and highlight
some of the novel factors involved in the antiproliferative effects
of SSA/DA treatment, it is also clear that an increased sample size
would strengthen our observation.
In conclusion, we have detected changes in transcriptional
profiles induced by SSA/DA therapy in PitNET tissue. The tumor
promoting factors MUC16, MACC1 and GRHL2 were
downregulated in PitNETs after SSA/DA therapy and in GH3
cell following octreotide treatment. Collagen related interactions
were detected after analyses of pathways and enrichment,
implicating ECM involvement in the anti-tumoral effects of
drug treatment. Further functional analyses are needed to
determine the impact of these molecules and their potential
role in response to SSA/DA treatment in patients with PitNET.DATA AVAILABILITY STATEMENT
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